Evidence map›Paper›PMID 40225968›Full record

ArticleOcular oncology and pathology2025

Evaluation of MRI Safety of Ru-106 Eye Applicators.

Michael C Y Tang, Lisa Klaassen, Marina Marinkovic, T H Khanh Vu, Gregorius P M Luyten, Carien L Creutzberg, Martijn Ketelaars, Jan-Willem M Beenakker

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Ocular oncology and pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Michael C Y TangDepartment of Ophthalmology, Leiden University Medical Center, Leiden, The Netherlands.
Lisa KlaassenDepartment of Ophthalmology, Leiden University Medical Center, Leiden, The Netherlands.
Marina MarinkovicDepartment of Ophthalmology, Leiden University Medical Center, Leiden, The Netherlands.
T H Khanh VuDepartment of Ophthalmology, Leiden University Medical Center, Leiden, The Netherlands.
Gregorius P M LuytenDepartment of Ophthalmology, Leiden University Medical Center, Leiden, The Netherlands.
Carien L CreutzbergDepartment of Radiation Oncology, Leiden University Medical Center, Leiden, The Netherlands.
Martijn KetelaarsDepartment of Radiation Oncology, Leiden University Medical Center, Leiden, The Netherlands.
Jan-Willem M BeenakkerDepartment of Ophthalmology, Leiden University Medical Center, Leiden, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Ruthenium-106 brachytherapy is a primary treatment for uveal melanoma (UM), the most common intra-ocular malignancy in adults. This study evaluated the safety of Ru-106 applicators at 3 Tesla (T) MRI and their impact on image quality. Methods: Magnetic attraction and eddy currents were tested on a 20-mm-diameter Ru-106 applicator using a nylon string and a porcine eye. Safety criteria were defined by ocular oncologists, comparing magnetic field interactions to the forces exerted on the eye during surgery. Five UM patients were scanned at 3T MRI with the applicator in situ using both conventional anatomical sequences and scans optimised to reduce metal artefacts. Results: Minimal magnetic interactions were observed. Eddy currents caused slight lagging during fast movements and temporary detachment of the applicator of the porcine eye in conditions that were considered unrealistic for clinical scans. Significant susceptibility artefacts compromised image quality of the affected eye. Conclusion: Patients with Ru-106 applicators can be safely used in 3T MRI with some simple precautions. MR image quality of the eye was poor due to major susceptibility artefacts; however, imaging of extra-ocular anatomy is feasible.

Indexed as

BrachytherapyChoroidal melanomaMedial rectus safetyOcular oncologyRadiation oncologyUveal melanoma

Identifiers

PMID40225968
PMCPMC11991723

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.